advance basal insulin glargine therapy: testing lixisenatide plus basalinsulin versus insulin glulisine either as basal-plus or basal-bolus intype 2 diabetes: the GetGoal Duo-2 trial. Diabetes Care . 2016;39: 1318-1328. 8.Diamant M, Nauck MA, Shaginian R, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type2 diabetes. Diabetes Care . 2014;37:2763-2773. 9.Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basalinsulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care . 2013;36:2489-2496. 10.Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized,placebo-controlled study (GetGoal-Duo 1). Diabetes Care . 2013;36: 2497-2503.